Fennec Pharmaceuticals Sees Robust Q1 Growth
Company Announcements

Fennec Pharmaceuticals Sees Robust Q1 Growth

Fennec Pharmaceuticals (TSE:FRX) has released an update.

Fennec Pharmaceuticals has reported a strong start to 2024 with first-quarter net revenues of $25.4 million, buoyed by an $18 million licensing deal with Norgine for the commercialization of PEDMARQSI™ in select international markets. The company has also solidified its cash position, boasting $51 million in reserves, and sees potential for significant market growth following an exclusive amendment specifying PEDMARK®’s unique formulation. These financial and strategic advances position the company favorably in the outpatient oncology sector.

For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskFennec Pharmaceuticals Reports Strong Q3 Results
TipRanks Auto-Generated NewsdeskFennec Pharmaceuticals Reports Q3 2024 Financial Results
TheFlyFennec price target lowered to $15 from $22 at Maxim
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App